{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:53:06Z","timestamp":1780483986345,"version":"3.54.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Modulation of the gut microbiome could favorably alter the hepatic venous pressure gradient (HVPG) in cirrhosis and portal hypertension (PH).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Aim<\/jats:title>\n<jats:p>This meta-analysis was to evaluate the effects of microbiome-targeted therapies (MTTs) on HVPG in persons with cirrhosis and PH.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>PubMed, The Cochrane Library, Embase, Web of Science and Scopus were searched for randomized clinical trials (RCTs) analyzing the effects on HVPG in people with cirrhosis who received MTTs. Clinical outcomes were pooled using RevMan5.3 software. A trial sequential analysis was applied to calculate the required information size and evaluate the credibility of the meta-analysis results.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of six studies were included. MTTs were associated with a reduction of 1.22 mm Hg in HVPG (95% CI: -2.31, -0.14 mmHg, P = 0.03). Subgroup analysis showed a greater reduction with longer duration (-1.88 mmHg;95% CI: -3.23, -0.53; P = 0.006). In the trial sequential analysis of HVPG reduction, the cumulative Z curve crossed the traditional significance boundary without the achievement of required information size (330).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>MTTs may be associated with a reduction in HVPG in patients with cirrhosis and PH. Microbiome-targeted therapies merit additional large-sample studies to define the efficacy of HVPG.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec006\">\n<jats:title>Systematic review registration<\/jats:title>\n<jats:p>PROSPERO 2020: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD4202021609\" xlink:type=\"simple\">CRD4202021609<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0273231","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T18:26:10Z","timestamp":1661883970000},"page":"e0273231","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"given":"Haonan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-6719","authenticated-orcid":true,"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"pone.0273231.ref001","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.mayocp.2018.12.020","article-title":"Portal Hypertension and Related Complications: Diagnosis and Management","volume":"94","author":"DA Simonetto","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"pone.0273231.ref002","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"G Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"pone.0273231.ref003","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2468-1253(18)30232-2","article-title":"Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension","volume":"3","author":"X Qi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0273231.ref004","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3748\/wjg.v26.i40.6111","article-title":"Cirrhotic portal hypertension: From pathophysiology to novel therapeutics","volume":"26","author":"LS Gunarathne","year":"2020","journal-title":"World J Gastroenterol"},{"key":"pone.0273231.ref005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MEG.0000000000000812","article-title":"Hemodynamic response to primary prophylactic therapy with nonselective beta-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis","volume":"29","author":"AJ Kerbert","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"pone.0273231.ref006","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cgh.2019.05.050","article-title":"Lowering Portal Pressure Improves Outcomes of Patients with Cirrhosis, With or Without Ascites: A Meta-Analysis","volume":"18","author":"L Turco","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0273231.ref007","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12072-021-10135-4","article-title":"Regression of portal hypertension: underlying mechanisms and therapeutic strategies","volume":"15","author":"S Selicean","year":"2021","journal-title":"Hepatol Int"},{"key":"pone.0273231.ref008","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/hep.30220","article-title":"Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis","volume":"69","author":"M Sharma","year":"2019","journal-title":"Hepatology"},{"key":"pone.0273231.ref009","first-page":"CD011510","article-title":"Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.","volume":"10","author":"AP Zacharias","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0273231.ref010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome.","volume":"15","author":"A Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0273231.ref011","doi-asserted-by":"crossref","first-page":"100","DOI":"10.21037\/hbsn.2020.03.27","article-title":"The gut-liver axis as a target of liver disease management","volume":"10","author":"C Mandato","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"pone.0273231.ref012","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/17474124.2018.1481747","article-title":"Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.","volume":"12","author":"FR Ponziani","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"pone.0273231.ref013","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.3748\/wjg.v25.i39.5897","article-title":"Gut-liver axis signaling in portal hypertension","volume":"25","author":"B Simbrunner","year":"2019","journal-title":"World J Gastroenterol"},{"key":"pone.0273231.ref014","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/liv.13264","article-title":"High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis","volume":"37","author":"D Agiasotelli","year":"2017","journal-title":"Liver Int"},{"key":"pone.0273231.ref015","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"V Arroyo","year":"2021","journal-title":"J Hepatol"},{"key":"pone.0273231.ref016","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/apt.15515","article-title":"Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy","volume":"50","author":"C Labenz","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0273231.ref017","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00109-019-01746-4","article-title":"AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model","volume":"97","author":"L Hu","year":"2019","journal-title":"J Mol Med (Berl)"},{"key":"pone.0273231.ref018","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-139-3-200308050-00008","article-title":"The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial","volume":"139","author":"B Rasaratnam","year":"2003","journal-title":"Ann Intern Med"},{"key":"pone.0273231.ref019","doi-asserted-by":"crossref","first-page":"111334","DOI":"10.1016\/j.biopha.2021.111334","article-title":"Link between microbiota and hypertension: Focus on LPS\/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics","volume":"137","author":"A Grylls","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"pone.0273231.ref020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/jhep.2003.50038","article-title":"Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement","volume":"37","author":"A Albillos","year":"2003","journal-title":"Hepatology"},{"key":"pone.0273231.ref021","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/liv.12172","article-title":"Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial","volume":"33","author":"N Gupta","year":"2013","journal-title":"Liver Int"},{"key":"pone.0273231.ref022","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/liv.12280","article-title":"VSL#3 (R) probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis.","volume":"33","author":"S Jayakumar","year":"2013","journal-title":"Liver Int"},{"key":"pone.0273231.ref023","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1478-3231.2008.01850.x","article-title":"Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial","volume":"29","author":"W Kemp","year":"2009","journal-title":"Liver Int"},{"key":"pone.0273231.ref024","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.28898","article-title":"Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial","volume":"65","author":"N Kimer","year":"2017","journal-title":"Hepatology"},{"key":"pone.0273231.ref025","doi-asserted-by":"crossref","first-page":"702","DOI":"10.5009\/gnl16478","article-title":"Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study","volume":"11","author":"YL Lim","year":"2017","journal-title":"Gut Liver"},{"key":"pone.0273231.ref026","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/liv.13986","article-title":"Potential mechanisms linking gut microbiota and portal hypertension","volume":"39","author":"G. Baffy","year":"2019","journal-title":"Liver Int"},{"key":"pone.0273231.ref027","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","author":"R de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"pone.0273231.ref028","first-page":"228","article-title":"Multidrug-resistant bacterial infections in patients with liver cirrhosis in a tertiary referral hospital","volume":"42","author":"S Bejar-Serrano","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"pone.0273231.ref029","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/jgh.14267","article-title":"Safety and efficacy of antibiotics among acutely decompensated cirrhosis patients","volume":"33","author":"S Habib","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0273231.ref030","doi-asserted-by":"crossref","first-page":"608498","DOI":"10.3389\/fimmu.2021.608498","article-title":"Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis.","volume":"12","author":"Y Fan","year":"2021","journal-title":"Front Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T18:27:06Z","timestamp":1661884026000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273231"}},"subtitle":[],"editor":[{"given":"George","family":"Vousden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273231","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}